$AMRZ

BofA downgrades Amrize stock on growth concerns, cuts price target

BofA downgraded Amrize (NYSE:AMRZ) to Underperform, cutting its price target to $40 from $50. The firm cited growth concerns, including risks to U.S. cement prices, Canada macro conditions, and hurricane season impacts. Amrize's stock is down 30% year-to-date, trading at $37.25. Other analysts have also adjusted their price targets and ratings.

Original reporting
Published Oct 2, 2026, 7:32 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 7:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$AMRZ
Bearish
high confidence
Mentioned
$AMRZ
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$AMRZBearishMed
01

Why it matters

The downgrade reflects concerns over growth, pricing pressure, and macro conditions, likely prompting short‑term sell pressure.

02

Market read

Analyst downgrade of a mid‑cap materials stock provides a clear trading signal for investors and may affect sector sentiment.

03

What to watch

Potential upside from upcoming M&A activity in the sector or cost‑cutting initiatives.

Relevance 6/10Novelty 7/10Timing: pre‑market today

Background

Amrize Ltd is a spin‑off from Holcim focused on cement and roofing products, with exposure to U.S. cement prices and Canadian demand.

Company-level read

Ticker impact

$AMRZBearishHigh confidence
Context

BofA Securities downgraded Amrize Ltd (AMRZ) to Underperform and cut the price target to $40.

Expected impact

likely pressure as the market prices in the downgrade and target cut

Evidence & confidence

The downgrade is a fresh, material change in analyst view with a concrete new target, prompting traders to reassess valuation.

Market effects

Cement and construction materials sector may see broader scrutiny as growth concerns are highlighted.

U.S. and Canadian markets could see modest sell pressure on related peers.

Limited to investors tracking US‑listed building‑materials stocks.

Counterpoint

Some analysts still see upside if the company can stabilize roofing margins.

Key entities

  • Amrize Ltd

    U.S. listed cement and roofing products manufacturer (NYSE: AMRZ).

  • BofA Securities

    Downgraded Amrize to Underperform and cut price target.

Related articles

Low

Amrize (SWX:AMRZ) Reshuffles Building Envelope Leadership As Fair Value Stays In Focus

Amrize (SWX:AMRZ) appointed Mario Gross as President of its Building Envelope division following Jake Gosa's resignation. The company's shares trade at CHF32.07, down 15.3% over the past month and 28.5% over the last quarter. Analysts suggest a fair value of CHF46.66, citing potential earnings power and margin expansion from the ASPIRE synergy program. The P/E ratio is 17.3x, compared to an estimated fair ratio of 30.5x and a peer average of 48.6x.

High

BofA downgrades Amrize to underperform, cuts price target on slower growth outlook

Bank of America downgraded Amrize to Underperform, cutting its price target to $40 from $50 due to slower earnings growth, market risks, and valuation concerns. The brokerage lowered its 2027-28 adjusted EBITDA and EPS estimates, citing stable U.S. cement prices, Canadian demand pressure from U.S. tariffs, and vulnerable roofing margins. BofA forecasts adjusted EBITDA growth of 3% and adjusted EPS growth of 6% annually over 2026-28, excluding large acquisitions. The bank also trimmed its buildin

$AMRZMed

BofA downgrades Amrize stock on growth concerns, cuts price target to $40

BofA Securities downgraded Amrize Ltd (NYSE:AMRZ) to Underperform, cutting its price target to $40 from $50. The stock is near its 52-week low, down 20% YTD. BofA reduced 2027-28 EBITDA estimates by 3%, citing growth concerns, U.S. cement price stability, and Canada macro risks. Amrize's Q2 earnings missed estimates, though revenue beat forecasts. Other analysts also downgraded the stock due to earnings misses and management changes.

High

Why is Amrize stock sliding today?

Amrize AG (AMRZ) fell 2.9% to CHF 34.13 after JPMorgan downgraded it to Neutral, citing executive departures and missed earnings. The stock hit a 52-week low of CHF 33.64, with JPMorgan lowering its price target to $52 from $57. The broader market showed no significant movement, indicating the decline is company-specific.